Ontology highlight
ABSTRACT:
SUBMITTER: Bautista F
PROVIDER: S-EPMC6809794 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
Open forum infectious diseases 20191023 10
This randomized phase 1b study evaluated the pharmacokinetics/pharmacodynamics of conventional-dose (30-75 mg twice daily [BID]) vs triple-dose (90-225 mg BID; weight-adjusted) oseltamivir for treatment of influenza in severely immunocompromised children <13 years. Oseltamivir carboxylate (OC) C<sub>max</sub> and AUC<sub>0-12h</sub> were ~2-fold higher with triple-dose vs conventional-dose oseltamivir. Increased dose/exposure of oseltamivir/OC did not improve virological outcomes or reduce viral ...[more]